Dossier assessment
Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Adults with relapsing remitting multiple sclerosis (RRMS) |
Result of dossier assessment:
| Treatment-naive patients or patients whose RRMS is not highly active under disease-modifying therapy: proof of considerable added benefit. Highly active RRMS despite therapy: proof of non-quantifiable (at least considerable) added benefit for men; for women: added benefit not proven. |
Additional information
Federal Joint Committee (G-BA)
07.01.2021 A G-BA decision was published.
Project details
- Project no.
- A20-59
- Commission
- Commission awarded on 15.07.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the decides of the GBA website.
Connected Projects
-
Dossier assessment
Ozanimod (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed